HLA-A01 and HLA-B27 Supertypes, but Not HLA Homozygocity, Correlate with Clinical Outcome among Patients with Non-Small Cell Lung Cancer Treated with Pembrolizumab in Combination with Chemotherapy.

Afaf Abed, Anna Reid, Ngie Law, Michael Millward, Elin S Gray

Abstract read

In one paragraph

Article in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it

0cells of the map it votes in

2citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

Resource: A compendium of HLA types and expression in pediatric cancer models.iScience · 2025
Article
Association of HLA-A*02:01 type with efficacy and toxicity of immune checkpoint inhibitor therapy in melanoma patients: a retrospective cohort study.BMC cancer · 2025
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Afaf AbedCentre for Precision Health, Edith Cowan University, Joondalup, WA 6027, Australia.ORCID 0000-0001-7506-3362

Anna ReidCentre for Precision Health, Edith Cowan University, Joondalup, WA 6027, Australia.ORCID 0000-0002-4588-1679

Ngie LawDepartment of Medical Oncology, Sir Charles Gairdner Hospital, Nedlands, WA 6009, Australia.ORCID 0000-0002-9333-0265

Michael MillwardSchool of Medicine, University of Western Australia, Crawley, WA 6009, Australia.

Elin S GrayCentre for Precision Health, Edith Cowan University, Joondalup, WA 6027, Australia.ORCID 0000-0002-8613-3570

Funding

Cancer Council of Western Australia FellowshipCentre for Precision Health at ECU A higher degree by research award schemeFiona Stanley Hospital, Murdoch, Western Australia Early investigator grantInternational Association for the Study of Lung Cancer Foundation Fellowship

6 · The paper itself

Abstract

introductionMaximal heterozygosity on the human leukocyte antigen (HLA) loci has been found to be associated with improved survival and development of immune-related adverse events (irAEs) among NSCLC patients treated with immunotherapy. Here, we investigated the effect of germline HLA-I/-II on clinical outcomes among NSCLC patients treated with first-line pembrolizumab in combination with chemotherapy.

methodWe prospectively recruited patients with NSCLC who were commencing first-line pembrolizumab in combination with chemotherapy. DNA from white blood cells was used for high-resolution HLA-I/II typing.

resultsOf the 65 patients recruited, 53 complied with the inclusion criteria. We did not find an association between HLA-I/-II homozygosity and clinical outcome among the studied population. However, the presence of HLA-A01 was associated with unfavourable PFS (HR = 2.32, 95%CI 1.13-4.77,

conclusionsThe absence of association between genomic HLA-I/-II homozygosity and clinical outcome among patients with advanced NSCLC treated with pembrolizumab in combination with chemotherapy might reflect a diminished role for HLA molecules among patients with low or no PD-L1. HLA-A01 and HLA-B27 might have a role in predicting clinical outcomes among this cohort of patients. Further studies are needed to explore biomarkers for this group of patients.

Indexed as

biomarkerschemotherapygenomic HLAimmunotherapyNSCLC

Identifiers

PMID39272960

DOI10.3390/cancers16173102

PMCPMC11394546

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.